Harmony Biosciences Holdings (HRMY) Gains from Investment Securities (2019 - 2026)
Harmony Biosciences Holdings recorded quarterly Gains from Investment Securities of $560000.0 in Q1 2026, up 101.64% quarter-over-quarter from -$34.1 million in Q4 2025, and down 92.98% year-over-year from $8.0 million in Q1 2025.
Harmony Biosciences Holdings' Gains from Investment Securities history runs 8 years deep, the most recent figure standing at $560000.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities fell 92.98% year-over-year to $560000.0; the TTM figure through Mar 2026 stood at -$31.2 million (down 491.59% YoY), while the FY2025 annual figure was $7.9 million, up 9.85% from the prior year.
- Gains from Investment Securities came in at $560000.0 for Q1 2026 at Harmony Biosciences Holdings, up from -$34.1 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $11.6 million in Q4 2022 to a low of -$36.0 million in Q4 2023.
- A 5-year average of -$1.3 million and a median of $560000.0 in 2026 frame the typical range for Gains from Investment Securities.
- On a YoY basis, Gains from Investment Securities climbed as much as 28729.11% in 2025 and fell as far as 1962.64% in 2025.
- Harmony Biosciences Holdings' Gains from Investment Securities stood at $11.6 million in 2022, then sank by 410.51% to -$36.0 million in 2023, then surged by 105.08% to $1.8 million in 2024, then sank by 1962.64% to -$34.1 million in 2025, then jumped by 101.64% to $560000.0 in 2026.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered $560000.0, -$34.1 million, and $8.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Harmony Biosciences Holdings | 1.83 Bn | 1.19 Bn | 170.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 560,000.00 |
| Mar 31, 2026 | 560,000.00 |
| Dec 31, 2025 | -34.11 Mn |
| Dec 31, 2025 | -34.11 Mn |
| Sep 30, 2025 | 7.98 Mn |
| Sep 30, 2025 | 7.98 Mn |
| Jun 30, 2025 | 8.01 Mn |
| Jun 30, 2025 | 8.01 Mn |
| Mar 31, 2025 | 7.98 Mn |
| Mar 31, 2025 | 7.98 Mn |
| Dec 31, 2024 | 1.83 Mn |
| Dec 31, 2024 | 1.83 Mn |
| Sep 30, 2024 | 86,394.00 |
| Sep 30, 2024 | 86,394.00 |
| Jun 30, 2024 | 27,791.00 |
| Jun 30, 2024 | 27,791.00 |
| Mar 31, 2024 | 467,000.00 |
| Mar 31, 2024 | 467,000.00 |
| Dec 31, 2023 | -36.03 Mn |
| Dec 31, 2023 | -36.03 Mn |
| Sep 30, 2023 | 6.26 Mn |
| Sep 30, 2023 | 6.26 Mn |
| Jun 30, 2023 | 194,620.00 |
| Jun 30, 2023 | 194,620.00 |
| Mar 31, 2023 | 99,797.00 |
| Mar 31, 2023 | 99,797.00 |
| Dec 31, 2022 | 11.60 Mn |
| Dec 31, 2022 | 11.60 Mn |
| Sep 30, 2022 | 1.53 Mn |
| Sep 30, 2022 | 1.53 Mn |
| Jun 30, 2022 | 87,330.00 |
| Jun 30, 2022 | 87,330.00 |
| Mar 31, 2022 | 1.38 Mn |
| Mar 31, 2022 | 1.38 Mn |
| Dec 31, 2021 | 1.96 Mn |
| Dec 31, 2021 | 1.96 Mn |
| Sep 30, 2021 | 5.98 Mn |
| Sep 30, 2021 | 5.98 Mn |
| Jun 30, 2021 | 1.30 Mn |
| Jun 30, 2021 | 1.30 Mn |
| Mar 31, 2021 | 1.11 Mn |
| Mar 31, 2021 | 1.11 Mn |
| Sep 30, 2020 | 2.81 Mn |
| Sep 30, 2020 | 2.81 Mn |
| Jun 30, 2020 | 438,000.00 |
| Jun 30, 2020 | 438,000.00 |
| Mar 31, 2020 | 1.15 Mn |
| Mar 31, 2020 | 1.15 Mn |
| Dec 31, 2019 | 495,000.00 |
| Dec 31, 2019 | 495,000.00 |